31 August 2026 **ASX ANNOUNCEMENT**

CONNEQT revenue rises 77% as commercial momentum builds through FY26

Highlights

- **FY26 revenue increased 77% to $6.30m from $3.55m in FY25, driven primarily by growth in CONNEQT Pulse sales.**
- **Net loss reduced 40% to $10.86m from $18.19m in FY25. The FY25 result included a $4.72m fair-value loss on investments.**
- **Total expenses reduced 22% to $18.84m, including a 67% reduction in product development and regulatory expenditure and an 11% reduction in employee costs.**
- **H2 revenue increased to approximately $4.0m, 76% above H1 revenue of $2.3m. The H2 loss reduced 19% to approximately $4.9m.**
- **Customer cash receipts increased 65% to $5.65m for FY26.**

CONNEQT Health Limited (ASX: CQT) ("CONNEQT" or "the Company") has reported revenue of $6.30 million for the year ended 30 June 2026, an increase of 77% from FY25, and a 40% reduction in statutory net loss to $10.86 million.

Revenue growth was driven primarily by CONNEQT Pulse sales as the consumer business expanded through FY26. Research, clinical and pharmaceutical activities also contributed to the Company's revenue base.

Total expenses declined 22% to $18.84 million. Product development and regulatory expenditure declined 67% following the transition of outsourced overseas software development resources to the Company's Australian operations. Employee costs declined 11%. The FY25 result included a $4.72 million fair-value loss on investments.

Customer cash receipts increased 65% to $5.65 million during FY26.

Second-half revenue growth

Revenue increased to approximately $4.0 million in H2, 76% above the $2.3 million generated in H1. The Company's net loss reduced from approximately $6.0 million in H1 to $4.9 million in H2, an improvement of 19%.

The H2 revenue increase was led by continued growth in CONNEQT Pulse sales. March quarter Pulse sales were slightly ahead of the December quarter, with a temporary supply constraint affecting large cuffs during February. Supply normalised before quarter end. Consumer revenue then increased 21% in the June quarter to a record $1.3 million, with Pulse unit sales increasing 33% to 3,574 devices.

Research and clinical activity also contributed to H2 revenue. Research activities across pharmaceutical, academic, clinical and international markets generated approximately $2.3 million in FY26, including approximately $0.8 million in the June quarter.

The substantial increase in second-half revenue contributed to the smaller H2 loss. The lower cost structure established through the centralisation of engineering and development helped contain operating expenditure as CONNEQT continued to invest in Pulse marketing and inventory to support growth.

Craig Cooper, CEO, CONNEQT Health:

"FY26 was the year we began to see the commercial model we have been building translate into the financial results. Revenue increased 77% for the year, led by Pulse. That momentum continued through the second half, with H2 revenue 76% higher than H1 and the second-half loss reducing by 19%.

"At the beginning of the year our priorities were clear: grow Pulse sales, build recurring enterprise revenue and advance our software platform. We made progress against each of those priorities during FY26 and maintained a disciplined approach to our operating cost base.

"Pulse has become the primary commercial growth engine for the business and continued to grow through the March and June quarters. Our research and clinical business also made a meaningful contribution to revenue. We also began establishing recurring revenues through enterprise subscriptions and digital services.

"CONNEQT enters FY27 focused on growing Pulse sales, increasing enterprise customer adoption and recurring revenue, expanding Care+ and other digital revenues, and progressing the FDA regulatory pathway for SphygmoCloud as we continue to maintain a disciplined approach to operating costs and capital management."

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations
Ben Henri
ben.henri@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").

Appendix 4E Preliminary Final Report
For the Year Ended 30 June 2026

1. *Company Details*

Name of entity:	CONNEQT Health Limited
ABN:	81 113 252 234
Reporting period	For the year ended 30 June 2026
Previous reporting period	For the year ended 30 June 2025

2. *Results for Announcement to the Market*

	30 June 2026 $	30 June 2025 $	% change to prior year	
Revenue from ordinary activities	6,295,285	3,551,284	Up	**77%**
Loss from ordinary activities for the period after tax attributable to members	(10,857,967)	(18,193,976)	Down	**40%**
Net loss for the period attributable to members	(10,857,967)	(18,193,976)	Down	**40%**

3. *Review of Operations and Financial Results*

Revenue and Expenses
Revenue from ordinary activities increased 77% to $6,295,285 (FY2025: $3,551,284), driven primarily by sales of the Pulse device.

Net loss for the year decreased to $10,857,967 (FY2025: $18,193,976), an improvement of $7,336,009 (40%), largely reflecting a reduction in total expenses following the implementation of the cost reduction initiatives in late FY25 and the non-recurrence of the $4,722,153 fair value loss on investments recognised in FY2025.

Total expenses decreased 22% to $18,839,941 (FY2025: $24,299,486), primarily driven by the non-recurrence of the fair value loss noted above, together with a $1,476,804 (67%) reduction in product development expenditure, as the FY2025 figure included costs associated with overseas outsourced software development resources which have since been transitioned in-house to Australia. Employee benefits expense decreased $1,040,776 (11%) despite this transition, reflecting the full-year impact of headcount and salary cost-saving initiatives commenced in FY2025. The cost reductions were partially offset by a $2,285,930 increase in marketing and sales expense, reflecting costs of marketing the Pulse device, and a $740,819 increase in cost of goods sold consistent with higher sales volumes.

Statement of Financial Position
The Group's net asset position moved from net assets of $633,507 at 30 June 2025 to a net liability position of $(228,046) at 30 June 2026, driven by an increase in current liabilities and the net loss for the year, partially offset by capital raised during the period. Net Assets would have been increased to $1,046,954 on conversion of the C2 Ventures Pty Ltd unsecured loans as detailed below.

Current financial liabilities at 30 June 2026 include $1.275m in unsecured loans from C2 Ventures Pty Ltd, a company owned by Directors Niall Cairns and Craig Cooper, forming part of their commitment to contribute $1.5m towards the June 2026 placement. Formal shareholder approval for the issue of shares to satisfy these loans will be sought at the Extraordinary General Meeting scheduled for 15 September 2026.

As the $1.275m in loans from C2 Ventures Pty Ltd are committed to be converted into equity (subject to shareholder approval at the Extraordinary General Meeting on 15 September 2026), the Group's net liability position of $(228,046) at 30 June 2026 would, on conversion, increase to net assets of $1,046,954.

Total current assets decreased 1% to $7,165,444 (FY2025: $7,239,009), reflecting an increase in trade and other receivables to $977,739 (FY2025: $312,140), driven by improved research sales in the second half of the year. This was offset by a 41% decrease in inventory to $1,180,440, as opening stock was sold down during the year. Pulse device inventory continued to turn over, with stock replenished subsequent to year end.

Total current liabilities increased 11% to $8,899,587 (FY2025: $8,011,240), primarily due to the increase in financial liabilities noted above.

Cashflows
Net cash used in operating activities decreased to $9,713,242 (FY2025: $10,896,357). Receipts from customers increased to $5,654,843 (FY2025: $3,427,435), consistent with the increase in revenue, which more than offset an increase in payments to suppliers and employees to $16,740,272 (FY2025: $16,575,087).

Net cash provided by financing activities was $9,859,677 (FY2025: $12,873,680), reflecting placements completed during the year together with $4,275,000 in convertible note and unsecured loan funding from C2 Ventures, of which $1.275m remains outstanding as noted above.

4. Dividends

No dividends have been paid or proposed by CONNEQT Health Limited during the year.

5. Net tangible assets per security

	Current Period 2026 Cents per share	Previous Period 2025 Cents per share
Net tangible asset backing per ordinary share	(0.06)	0.02

6. Control gained or lost over entities

No gain or loss of control over any entities occurred in the reporting period.

7. Details of associates and joint venture entities

Name of entity	Percentage holding	Contribution to net profit/(loss)
inHealth Medical Services, Inc.	28.05% (2025: 7.64%)	$22,381 (2025: nil)

On 30 September 2025, CONNEQT Health converted its inHealth Convertible Note investment into 630,000 shares of inHealth's common stock, increasing the Group's ownership from 7.64% to 28.05%. From that date, inHealth Medical Services, Inc. has been accounted for as an associate under AASB 128 Investments in Associates and Joint Ventures.

8. Significant information needed by an investor

Further significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position will be included in the annual report.

9. Foreign entities set of accounting standards used in compiling the report (IAS)

The Company is not a foreign entity. Australian Accounting Standards have been applied consistently across all entities in the Group.

10. Audit status

The report is based on accounts that are in the process of being audited. It is anticipated that the independent auditor's review report will include an Emphasis of Matter paragraph regarding a material uncertainty related to going concern, as will be disclosed in the notes to the financial statements.

11. Compliance statement

The financial report includes the consolidated financial statements and notes of CONNEQT Health Limited and controlled entities ('Consolidated Group' or 'Group'). The financial report has been prepared in accordance with ASX Listing Rule 4.3A. The financial report is prepared on an accruals basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

Niall Cairns
Executive Chairman

Dated: 31 August 2026

Preliminary Final Report Contents

CONNEQT HEALTH LIMITED
AND CONTROLLED ENTITIES
ABN 81 113 252 234

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR YEAR ENDED 30 JUNE 2026

	Note	2026 $	2025 $
Revenue	4	**6,295,285**	3,551,284
Other income	4	**1,664,308**	2,554,226
Total revenue and other income		**7,959,593**	6,105,510
Cost of goods sold		**(1,737,058)**	(996,239)
Bad debts reversal (expense)		**40,833**	(253,567)
Marketing and sales expense		**(3,546,811)**	(1,260,881)
Product development and regulatory expense		**(738,138)**	(2,214,942)
Occupancy expense		**(281,309)**	(282,982)
Employee benefits expense		**(8,587,478)**	(9,628,254)
Share based payments expense		**(527,048)**	(645,810)
Administration expense		**(2,505,141)**	(2,638,999)
Interest expense		**(576,342)**	(662,466)
Inventory write-down reversal (expense)		**47,166**	(824,502)
Amortisation expense		**(206,393)**	(103,729)
Fair value loss on investments		**-**	(4,722,153)
Fair value loss on financial assets and liabilities		**(222,222)**	(64,962)
Total expenses		**(18,839,941)**	(24,299,486)
Share of profit of associate		**22,381**	-
Net loss before income tax expense		**(10,857,967)**	(18,193,976)
Income tax expense		**-**	-
Net loss for the year		**(10,857,967)**	(18,193,976)
Other comprehensive loss for the period, net of tax:			
Exchange differences on translating to the presentation currency		**(58,790)**	(53,087)
Total comprehensive loss for the period attributable to members of the parent entity		**(10,916,757)**	(18,247,063)
Basic loss per share (cents)		**(1.8)**	(5.1)
Diluted loss per share (cents)		**(1.8)**	(5.1)

These financial statements should be read in conjunction with the accompanying notes.

CONNEQT HEALTH LIMITED
AND CONTROLLED ENTITIES
ABN 81 113 252 234

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2026

	2026	2025
	$	$
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	**2,566,332**	2,433,097
Trade and other receivables	**977,739**	312,140
Inventory	**1,180,440**	1,985,749
Other current assets	**2,440,933**	2,508,023
TOTAL CURRENT ASSETS	**7,165,444**	7,239,009
NON-CURRENT ASSETS		
Property, plant and equipment	**525,847**	837,063
Intangible assets	**309,590**	515,983
Financial assets	**-**	649,119
Investments in associates	**666,387**	-
Other non-current assets	**83,816**	83,519
TOTAL NON-CURRENT ASSETS	**1,585,640**	2,085,684
TOTAL ASSETS	**8,751,084**	9,324,693
LIABILITIES		
CURRENT LIABILITIES		
Trade and other payables	**4,267,081**	4,090,087
Unearned revenue	**340,631**	462,058
Provisions	**537,686**	460,080
Financial liabilities	**2,379,675**	1,728,244
Lease liabilities	**221,068**	191,504
Borrowings	**1,153,446**	1,079,267
TOTAL CURRENT LIABILITIES	**8,899,587**	8,011,240
NON-CURRENT LIABILITIES		
Provisions	**18,522**	12,141
Financial liabilities	**-**	381,680
Lease liabilities	**61,021**	286,125
TOTAL NON-CURRENT LIABILITIES	**79,543**	679,946
TOTAL LIABILITIES	**8,979,130**	8,691,186
NET ASSETS / NET (LIABILITES)	**(228,046)**	633,507
EQUITY		
Contributed equity	**112,472,117**	102,890,051
Reserves	**1,385,175**	2,628,122
Accumulated losses	**(114,085,338)**	(104,884,666)
TOTAL EQUITY	**(228,046)**	633,507

CONNEQT HEALTH LIMITED
AND CONTROLLED ENTITIES
ABN 81 113 252 234

These financial statements should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CASH FLOWS FOR YEAR ENDED 30 JUNE 2026

	2026	2025
	$	$
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	**5,654,843**	3,427,435
Cash receipts from grants	**-**	793,155
Payments to suppliers and employees	**(16,740,272)**	(16,575,087)
Receipt for R&D tax incentives	**1,631,519**	1,455,105
Interest paid	**(259,332)**	-
Interest received	**-**	3,035
Net cash used in operating activities	**(9,713,242)**	(10,896,357)
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments to acquire property, plant and equipment	**(13,610)**	(26,328)
Net cash used in investing activities	**(13,610)**	(26,328)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from shares issued	**6,415,346**	8,547,140
Share issue costs	**(483,732)**	(768,767)
Proceeds from Funding Commitment Agreement	**-**	5,478,766
Proceeds from issue of convertible debt	**2,000,000**	-
Proceeds from issue of unsecured loans	**2,275,000**	-
Borrowings received	**1,115,000**	1,566,000
Borrowings repaid	**(1,079,267)**	(1,722,065)
Convertible notes repaid	**-**	-
Unmarketable Parcel Buy Back	**(144,653)**	
Lease payments	**(238,017)**	(227,394)
Net cash provided by financing activities	**9,859,677**	12,873,680
Net increase in cash held	**132,825**	1,950,995
Cash and cash equivalents at beginning of financial year	**2,433,097**	481,429
Effects of foreign currency exchange	**410**	673
Cash and cash equivalents at end of financial year	**2,566,332**	2,433,097

These financial statements should be read in conjunction with the accompanying notes.

CONNEQT HEALTH LIMITED
AND CONTROLLED ENTITIES
ABN 81 113 252 234

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR YEAR ENDED 30 JUNE 2025

	Shares on Issue	Reserves	Accumulated losses	Total
	$	$	$	$
Balance at 1 July 2024	**88,108,332**	**2,669,839**	**(86,690,690)**	**4,087,481**
Loss after income tax expense for the year	-	-	(18,193,976)	(18,193,976)
Other comprehensive loss for the year, net of tax – *Exchange differences on translation to the presentation currency*	-	(53,087)	-	(53,087)
Total comprehensive loss for the year		**(53,087)**	**(18,193,976)**	**(18,247,063)**
Transactions with equity holders in their capacity as owners:				
Capital placement	8,760,658	-	-	8,760,658
Shares issued on conversion of Funding Commitment Agreement	6,000,000	-	-	6,000,000
Shares issued on exercise of performance rights	691,875	(691,875)	-	-
Shares issued in lieu of payments to employees	79,291	-	-	79,291
Shares issued in lieu of payments to suppliers	29,851	-	-	29,851
Performance rights vesting expense	-	530,150	-	530,150
Options vesting expense	-	173,095	-	173,095
Costs of issuing share capital	(779,956)	-	-	(779,956)
Balance at 30 June 2025	**102,890,051**	**2,628,122**	**(104,884,666)**	**633,507**

These financial statements should be read in conjunction with the accompanying notes.

CONNEQT HEALTH LIMITED
AND CONTROLLED ENTITIES
ABN 81 113 252 234

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR YEAR ENDED 30 JUNE 2026

	Shares on Issue	Reserves	Accumulated losses	Total
	$	$	$	$
Balance at 1 July 2025	**102,890,051**	**2,628,122**	**(104,884,666)**	**633,507**
Loss after income tax expense for the year	-	-	(10,857,967)	(10,857,967)
Other comprehensive loss for the year, net of tax – *Exchange differences on translation to the presentation currency*	-	(58,790)	-	(58,790)
Total comprehensive loss for the year	**-**	**(58,790)**	**(10,857,967)**	**(10,916,757)**
Transactions with equity holders in their capacity as owners:				
Capital placement	7,720,320	-	-	7,720,320
Shares issued on conversion of convertible notes	2,222,222	-	-	2,222,222
Shares issued on exercise of performance rights	-	-	-	-
Shares issued in lieu of payments to directors and employees	255,910	-	-	255,910
Unmarketable Parcel Buyback	(144,654)	-	-	(144,654)
Performance rights vesting expense	-	346,881	-	346,881
Options vesting expense	-	126,257	-	126,257
Options / rights expired	-	(1,657,295)	1,657,295	-
Costs of issuing share capital	(471,732)	-	-	(471,732)
Balance at 30 June 2026	**112,472,117**	**1,385,175**	**(114,085,338)**	**(228,046)**

These financial statements should be read in conjunction with the accompanying notes.

1. General Information and Statement of Compliance

The financial report includes the consolidated financial statements and notes of CONNEQT Health limited and controlled entities ('Consolidated Group' or 'Group'). The financial report has been prepared in accordance with ASX Listing Rule 4.3A. The financial report is prepared on an accruals basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

2. Summary of Significant Accounting Policies

Principles of Consolidation
A controlled entity is any entity CONNEQT Health Limited has the power to control the financial and operating policies so as to obtain benefits from its activities.

All controlled entities have a 30 June 2026 financial year-end.

As at the reporting date, the assets and liabilities of all controlled entities have been incorporated into the consolidated financial statements as well as their results for the year ended.

All inter-company balances and transactions between entities in the Group, including any unrealised profits or losses, have been eliminated on consolidation. Accounting policies of subsidiaries have been changed where necessary to ensure consistencies with those policies applied by the Company.

Where controlled entities have entered or left the Group during the year, their operating results have been included/excluded from the date control was obtained or until the date control ceased.

Functional and presentation currency
The functional currency of the parent entity is Australian Dollars ("AUD") as the parent company is based in Australia and the majority of transactions take place in AUD. The financial statements are presented in AUD which is the presentational currency of the Group, which management have determined that this is the most relevant currency for the users of the financial statements.

3. Operating Segments

(a) Description of segments

In the 2026 financial year, the Group operated in one operating segment and has identified only one reportable segment being sales of cardiovascular devices and services to individuals, hospitals, clinics, research institutions and pharmaceutical companies.

Geographically, the Group prepares information based on the location of its customers, being:

- Americas (includes global pharmaceutical trials business)
- Europe (includes Middle East and Africa)
- Asia Pacific (includes Asia & Australia/NZ)

(b) Segmental information provided to the Board

2026	**Americas**	**Europe**	**Asia Pacific**	**Inter-segment eliminations**	**Consolidated**
	$	**$**	**$**	**$**	**$**
Sales to external customers	**5,863,711**	**183,591**	**247,983**	**-**	**6,295,285**
Intersegment sales		**-**	**89,625**	**(89,625)**	**-**
Total sales revenue	**5,863,711**	**183,591**	**337,608**	**(89,625)**	**6,295,285**
Other income	**107,054**	**-**	**1,557,254**	**-**	**1,664,308**
Total segment revenue/income	**5,970,765**	**183,591**	**1,894,862**	**(89,625)**	**7,959,593**
Segment result					
Loss before income tax	**(5,621,575)**	**(69,306)**	**(6,070,511)**	**903,425**	**(10,857,967)**
Income tax expense					**-**
Loss for the year					**(10,857,967)**
Segment assets	**4,141,473**	**-**	**92,526,741**	**(87,917,130)**	**8,751,084**
Segment liabilities	**45,545,299**	**-**	**66,423,811**	**(102,989,980)**	**8,979,130**

2025	**Americas**	**Europe**	**Asia Pacific**	**Inter-segment eliminations**	**Consolidated**
	$	**$**	**$**	**$**	**$**
Sales to external customers	2,484,613	434,231	632,440	-	3,551,284
Intersegment sales		-	749,004	(749,004)	-
Total sales revenue	2,484,613	434,231	1,381,444	(749,004)	3,551,284
Other income	810,544	-	1,743,682	-	2,554,226
Total segment revenue/income	3,295,157	434,231	3,125,126	(749,004)	6,105,510
Segment result					
Loss before income tax	(5,854,328)	398,566	(13,470,112)	731,898	(18,193,976)
Income tax expense					-
Loss for the year	(5,854,328)	398,566	(13,470,112)	731,898	(18,193,976)
Segment assets	8,213,756	-	87,721,355	(86,610,418)	9,324,693
Segment liabilities	45,810,480	-	65,534,539	(102,653,833)	8,691,186

4. Revenue

Disaggregation of revenue

Revenue is disaggregated by the country in which the customer is located as this depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.

2026	Americas	Europe	Asia Pacific	Consolidated
	$	$	$	$
Sale of goods	**4,435,188**	**181,231**	**240,658**	**4,857,077**
Lease revenue	**430,097**	**-**	**-**	**430,097**
Service revenue	**941,590**	**1,540**	**5,266**	**948,396**
Freight revenue	**56,836**	**820**	**2,059**	**59,715**
Total sales revenue	**5,863,711**	**183,591**	**247,983**	**6,295,285**
Other income	**107,054**	**-**	**1,557,254**	**1,664,308**
Total revenue/income	**5,970,765**	**183,591**	**1,805,237**	**7,959,593**

2025	Americas	Europe	Asia Pacific	Consolidated
	$	$	$	$
Sale of goods	1,924,485	424,060	616,405	2,964,950
Lease revenue	130,171	-	-	130,171
Service revenue	396,660	1,988	10,396	409,044
Freight revenue	33,297	8,183	5,639	47,119
Total sales revenue	2,484,613	434,231	632,440	3,551,284
Other income	810,544	-	1,743,682	2,554,226
Total revenue/income	3,295,157	434,231	2,376,122	6,105,510

For more information, please contact:

Investor Relations
Ben Henri
ben.henri@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CONNEQT Health

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes clinical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, all based on the Company's SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Securities Exchange (ASX: CQT).